Search terms
Results 1 - 1 of 1 - ordered by :

Compared with those allocated to placebo, CANTOS participants receiving canakinumab who achieved on-treatment IL-6 levels below the study median value of 1.65ng/L experienced a 32% reduction in major ...

European Heart Journal, Ridker, Paul M, Libby, Peter, MacFadyen, Jean G, Thuren, Tom, Ballantyne, Christie, Fonseca, Francisco, Koenig, Wolfgang, Shimokawa, Hiroaki, Everett, Brendan M, Glynn, Robert ...

Date : 07/10/2018 Item size : 362542 bytes